money moves

Houston-based carbon negative biotech startup closes series A round

The brother-sister team at Houston-based Cemvita Factory is celebrating its series A initial closing. Photo courtesy of Cemvita

A promising Houston startup using biotechnology to reduce carbon emissions is celebrating the initial closing of its series A fundraising round.

Cemvita Factory announced the news of its round closing, but didn't disclose the amount raised. 8090 Partners, a new investment group of entrepreneurs turned investors, led the round. Existing investor Oxy Low Carbon Ventures also contributed, along with Seldor Capital, Climate Capital, and others.

Founded by brother-sister team Moji and Tara Karimi in 2017, the company's technology biomimics photosynthesis to take carbon dioxide and turn it into something else. Cemvita uses this synthetic biology to decarbonize heavy industry across chemical manufacturing, mining, and oil and gas.

"Decarbonizing heavy industry is one of the most critical challenges in addressing climate change," says Moji Karimi, who serves as CEO, in a news release. "Synthetic biology is now primed to revolutionize heavy industries because of its inherent low-carbon advantages, and Cemvita is taking the lead in identifying and derisking the key applications."

Cemvita is currently working. with a number of clients — including Oxy, which announced its pilot in April — to reduce their carbon footprints.

"We believe the adoption rate and market size growth of our target applications will only accelerate due to the urgency for a low-carbon energy transition," Karimi continues. "The future of manufacturing will be low-carbon biomanufacturing and the future of mining will be sustainable biomining."

According to the release, the fresh funds will go toward launching Cemvita's bio-hydrogen solution, as well as to support construction and operation of a bio-ethylene pilot plant with Oxy. The pilot project, which reported success in the lab, is expected to scale.

"While synthetic biology has proven to be effective in re-imagining food and proteins, we've long held a firm belief in synthetic biology's promise in the heavy industrial space, but have waited until we've seen the right technology and team to drive real innovation in the sector," says Rayyan Islam, partner at 8090 Partners, in the release. "Cemvita's technology is a fundamental game-changer that provides a real economic solution and major players across heavy industry have taken serious notice."

It's not just investors and industrial players who have taken notice. Cemvita won the recent GS Beyond Energy Innovation Challenge from Cleantech.org. The company was also selected as a cohort member at Carbon2Value Initiative.

"Cemvita's technology is truly revolutionary in its use of CO2 and as a resource to provide viable economic solutions as more and more companies seek ways to reduce their carbon footprint. We remain impressed and excited about Cemvita's technology's positive impact on Earth and beyond," says Sidney N. Nakahodo, founder and general partner of Seldor Capital, in the release.

Trending News

Building Houston

 
 

Houston-based medical device and biotech startup Steradian Technologies has been recognized by the Bill and Melinda Gates Foundation. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

A female-founded biotech startup has announced that it has received a grant from the Bill & Melinda Gates Foundation.

Steradian Technologies has developed a breath-based collection device that can be used with diagnostic testing systems. Called RUMI, the device is non-invasive and fully portable and, according to a news release, costs the price of a latte.

“We are extremely honored to receive this award and be recognized by the Bill & Melinda Gates Foundation, a leader in global health. This funding will propel our work in creating deep-tech diagnostics and products to close the equity gap in global public health," says Asma Mirza, CEO and co-founder of Steradian Technologies, in the release. “The RUMI will demonstrate that advanced technology can be delivered to all areas of the world, ensuring the Global South and economically exploited regions receive access to high-fidelity diagnostics instead of solutions that are ill-suited to the environment.”

RUMI uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30-seconds, per the release, and will be the first human bio-aerosol specimen collector to convert breath into a fully sterile liquid sample and can be used for many applications in direct disease detection.

"As the healthcare industry continues to pursue less invasive diagnostics, we are very excited that the foundation has identified our approach to breath-based sample collection as a standout worthy of their support," says John Marino, chief of product development and co-founder. “We look forward to working with them to achieve our goals of better, faster, and safer diagnostics."

Founded in 2017, Steradian Technologies is funded and supported by XPRIZE, Johnson & Johnson’s Lung Cancer Initiative, JLABS TMCi, Capital Factory, Duke Institute of Global Health, and Johnson & Johnson’s Center for Device Innovation.

The amount granted by the Bill & Melinda Gates Foundation was not disclosed. The Seattle-based foundation is led by CEO Mark Suzman and co-chaired by Bill Gates and Melinda French Gatess.

Trending News